IHC studies revealed that the frequency of MDM2 expression in RCC patients with GG genotypes (5 of 10, 50%) was significantly higher than that of RCC patients with TT genotypes (2 of 15, 13%) and TG genotypes (4 of 15, 26%) [116]. This evidence concerns the gene MDM2 and renal cell carcinoma.